Scientia Vascular announced the FDA clearance of two uniquely engineered catheters: the Plato 17—a DMSO-compatible microcatheter—and the Socrates 38, an aspiration catheter engineered for ischemic stroke.
Currently in the midst of a limited market release, the Socrates 38 aspiration catheter is gathering feedback and clinical insights. This phase is crucial for executing the final stages of the strategic launch and bringing better, more advanced options to physicians treating stroke.
The Plato 17 microcatheter, compatible with DMSO, offers physicians control and stability for a multitude of neurovascular applications.
"Our FDA clearance is a significant milestone for Scientia Vascular. By applying proven microfabrication technology to catheters and designing our access and treatment devices for efficiency when used together, we're providing physicians the next generation of neurovascular access tools," said John Lippert, CEO of Scientia Vascular. "I am immensely grateful to our dedicated teams whose tireless efforts have made this FDA clearance milestone possible. Their commitment to excellence and innovation continues to drive our patient mission forward."
"We've seen what microfabrication can do in products like our Aristotle® 24 and Colossus wires in changing the standard of care for patient treatment in stroke, so it's rewarding to see the excitement and buzz surrounding microfabricated technology in catheters with our physician community," said Paul Fischer, Chief Commercial Officer for Scientia Vascular. "We are eager to see how these advanced technologies will enhance patient care and offer new possibilities for physicians treating a variety of neurovascular disease states."
